Conquering superbugs one view at a time
Earlier this year, I authored a piece on the urgent need for action in the antimicrobial resistance (AMR) or superbugs discussion. The piece shed light on our side event at the 67th World Health Assembly. Furthermore, it provided suggestions on how others can help.
But, what’s next? Is hosting a side event at the World Health Assembly enough? Does it deliver answers to this "catastrophic threat" that desperately needs our attention? Keeping these questions in mind, we utilised one of our communications platforms to invest in a series on Superbugs.
The Superbugs series brought forward four views on curbing AMR and underlined the need for multiple partners to work together.
With the Company View, we pointed out that healthcare professionals need appropriate tools to deliver right treatment at the right time.
With the Foundation View, we highlighted the need to incentivise solution providers – mainly the SMEs who may need funding.
With the Industry View, we explained the role of diagnostics in identifying antimicrobial resistance.
With the Physician’s View, we gave space for a physician to admit that, yes, part of the problem could be the patient-pleasing physicians.
What we didn't allow is finger pointing. We didn't let contributors to place blame. We also didn't let contributors make bold statements because it was important to let the dialogue remain real and genuine. Also, we wanted the series to encourage holistic solutions while keeping the various viewpoints in mind.
So, what’s next in the antimicrobial resistance discussion? Are we done? Is this as far as we can go with our efforts. The answer is simply, no. There's still a lot of work to be done. So stay tuned.
Teaser: Local and global champions combating AMR.